Online inquiry

IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3603MR)

This product GTTS-WQ3603MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LYPD3 gene. The antibody can be applied in Neoplasms research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_014400.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27076
UniProt ID O95274
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3603MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1143MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABP 215
GTTS-WQ6240MR IVTScrip™ mRNA-Anti-RABVgp4, CR57(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CR57
GTTS-WQ2530MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG 334
GTTS-WQ1408MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACA125
GTTS-WQ13209MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ14734MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-19A
GTTS-WQ11917MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MLN2045
GTTS-WQ13276MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-06252616
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW